Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5874669 | 0.92 | ATM (0.43) | L3MBTL1ATMCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL14228809 | 0.90 | ATM (0.44) | L3MBTL1ATMCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL5874399 | 0.88 | L3MBTL1 (0.39) | L3MBTL1ATMCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL442464 | 0.86 | L3MBTL1 (0.38) | L3MBTL1ATMCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL5874140 | 0.83 | ALDH1A1 (0.38) | L3MBTL1ATMCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL4631225 | 0.81 | KMT2A (0.41) | L3MBTL1CYP1A2MAPTMEN1KMT2A | |
| SCHEMBL5874880 | 0.81 | L3MBTL1 (0.47) | L3MBTL1CYP1A2MAPK1MAPTMEN1 | |
| SCHEMBL3443989 | 0.79 | SMN1; SMN2 (0.58) | L3MBTL1CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL442463 | 0.79 | CYP1A2 (0.48) | CYP1A2MAPK1SMN1; SMN2TSHRMEN1 | |
| SCHEMBL5737549 | 0.79 | L3MBTL1 (0.55) | L3MBTL1MAPK1TSHRMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569313-B2 | Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-20100305090-A1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305090-A1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | MMP7, DNPEP, METAP1 | L3MBTL1 2328/4885ATM 2553/4885CYP1A2 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.